Interleukin-17A Antagonist [EPC]

141913 reported adverse events

Drugs of this class: IXEKIZUMAB SECUKINUMAB

These side effects are most commonly reported by patients taking drugs of the Interleukin-17A Antagonist [EPC] class:

# Side effect Count
0 DRUG INEFFECTIVE 22933
1 PSORIASIS 18949
2 PAIN 11274
3 ARTHRALGIA 10033
4 FATIGUE 6450
5 MALAISE 6313
6 PRURITUS 6282
7 INJECTION SITE PAIN 5826
8 PSORIATIC ARTHROPATHY 5628
9 RASH 5449
See all common reactions for Interleukin-17A Antagonist [EPC]

Drugs of the Interleukin-17A Antagonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 REBOUND PSORIASIS 254 0.6165
1 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY 88 0.5057
2 LUPUS VULGARIS 57 0.4914
3 RED BLOOD CELL SEDIMENTATION RATE 105 0.4217
4 TONSILLAR ULCER 41 0.3361
5 MACULE 597 0.2856
6 NAIL PSORIASIS 119 0.2854
7 SWOLLEN JOINT COUNT INCREASED 244 0.2831
8 DEEP VEIN THROMBOSIS POSTOPERATIVE 89 0.2816
9 ENTHESOPATHY 322 0.2771
See all enriched reactions for Interleukin-17A Antagonist [EPC]